Wall Street drops as China stock slump stokes growth fears
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics
July 28, 2015 9:23 AM EDTCanaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More
Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale
July 28, 2015 9:13 AM EDTCanaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More
Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement
July 28, 2015 8:19 AM EDTAllergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.
Gerberry... More
Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO
July 28, 2015 8:12 AM EDTLeerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More
Raymond James Upgrades Beacon Roofing Supply (BECN) to Outperform
July 27, 2015 2:21 PM EDTRaymond James upgraded Beacon Roofing Supply (NASDAQ: BECN) from Market Perform to Outperform with a price target of $40.00.
For an analyst ratings summary and ratings history on Beacon Roofing Supply click here. For more ratings news on Beacon Roofing Supply click here.
Shares of Beacon Roofing Supply closed at $30.08 yesterday.
... MoreChina Internet Consumer Demand Remains Healthy, Buy 58.com (WUBA), Qunar (QUNR) - Pacific Crest
July 27, 2015 9:46 AM EDTPacific Crest analyst Cheng Cheng thinks investors should buy pullbacks in 58.com (NYSE: WUBA) and Qunar (NASDAQ: QUNR). He is also positive on Youku Tudou (NYSE: YOKU), Baidu.com (NASDAQ: BIDU) and Alibaba (NYSE:... More
